This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refractory). ONC201 is the first in its class of drugs that antagonize some specific cell receptors on cancer cells, leading to their destruction. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ONC201 and paclitaxel may work better in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer compared to paclitaxel alone.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of treatment related adverse events (AEs) (Part 1)
Timeframe: Up to 28 days
Incidence of dose limiting toxicities (DLT's) (Part 1)
Timeframe: Up to 28 days
Objective response rate (ORR) (Part 2)
Timeframe: Up to 1 year
Progression free survival (PFS) (Part 2)
Timeframe: From study treatment initiation to objective tumor progression or death, assessed up to 1 year